GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (STU:IF0) » Definitions » Sale Of Investment

InflaRx NV (STU:IF0) Sale Of Investment : €93.60 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Sale Of Investment?

InflaRx NV's sale of investment for the three months ended in Sep. 2024 was €22.05 Mil. It means InflaRx NV gained €22.05 Mil from selling investments. InflaRx NV's sale of investment for the trailing twelve months (TTM) ended in Sep. 2024 was €93.60 Mil.

Compared with last quarter (€25.69 Mil in Jun. 2024 ), InflaRx NV gained less money from selling investments in Sep. 2024 (€22.05 Mil).


InflaRx NV Sale Of Investment Historical Data

The historical data trend for InflaRx NV's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Sale Of Investment Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only 103.56 123.06 71.60 84.00 86.44

InflaRx NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.91 15.32 30.53 25.69 22.05

InflaRx NV Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €93.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InflaRx NV Sale Of Investment Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV Business Description

Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV Headlines

No Headlines